Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway

References

• Weston S, Coleman CM, Haupt R, et al. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo. J Virol. 2020 Oct 14;94(21):21.
   Web of Science ®Google Scholar
• Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. J Med Virol. 2020 Jul;92(7):770–775.
   PubMed Web of Science ®Google Scholar
• Satarker S, Ahuja T, Banerjee M, et al. Hydroxychloroquine in COVID-19: potential Mechanism of Action Against SARS-CoV-2. Curr Pharmacol Rep. 2020;24:1–9.
   Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug;2(1):69.
   PubMed Web of Science ®Google Scholar
• Rubino F, Amiel SA, Zimmet P, et al. New-Onset Diabetes in Covid-19. N Engl J Med. 2020 Aug 20;383(8):789–790.
   PubMed Web of Science ®Google Scholar
• Wasko MCM, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007 Jul 11;298(2):187–193.
   PubMed Web of Science ®Google Scholar
• Arora K, Gwinn WM, Bower MA, et al. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol. 2005 Jul 1;175(1):517–522.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Yoneda M, Ikeda F, et al. CD147/EMMPRIN acts as a functional entry receptor for measles virus on epithelial cells. J Virol. 2010 May;84(9):4183–4193.
   PubMed Web of Science ®Google Scholar
• Liu C, Von Brunn A, Zhu ZD. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19. Med Drug Discov. 2020 Sep 7:100056.
   Google Scholar
• Z-hz HB, Wei D, Zhang Z, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv. 2020.
   Google Scholar
• Ulrich H, Pillat MM. CD147 as a Target for COVID-19 Treatment: suggested Effects of Azithromycin and Stem Cell Engagement. Stem Cell Rev Rep. 2020 Jun;16(3):434–440.
   PubMed Web of Science ®Google Scholar
• Violaine Guérin V, Lévy P, Thomas J-L, et al. Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19. Asian Journal of Medicine and Health. 2020;18(7):45–55.
   Google Scholar
• FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. [cited; Available from: https://www.fda.gov/media/137250/download
   Google Scholar
• Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949.
   PubMed Web of Science ®Google Scholar
• Rodrigo Barbosa Esper M.D. PD, Rafael Souza da Silva M.D., Fernando Teiichi Costa Oikawa M.D., Ph.D., Marcelo Machado Castro M.D., Alvaro Razuk-Filho M.D., Ph.D., Pedro Benedito Batista Junior M.D., Sergio Wilhelm Lotze M.D., Cleber Nunes da Rocha M.D., Roberto de Sá Cunha Filho M.D., Saulo Emanuel Barbosa de Oliveira M.D, Philipe Leitão Ribeiro, M.D., Valéria Cristina Vigar Martins M.D., Fernando Silva Braga Bueno M.D., Priscila Ligeiro Gonçalves Esper M.D., Eduardo Fagundes Parrillo M.D. Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine. 2020. Available from: https://pgibertie.files.wordpress.com/2020/04/2020.04.15-journal-manuscript-final.pdf
   Google Scholar
• Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : a Randomized Trial.Ann Intern Med. 2020 Jul;173(8):16.
   Web of Science ®Google Scholar
• Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020 Aug 6;383(6):517–525.
   PubMed Web of Science ®Google Scholar
• Mitja O, Corbacho-Monne M, Ubals M, et al. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: a Randomized-Controlled Trial. Clin Infect Dis 2020 Jul 16.
   Google Scholar
• Derwand R, Scholz M, Zelenko VCOVID, * A case series showing the effects of hydroxychloroquine, azithromycin and zinc combined in hospitalization rates and death. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. Int J Antimicrob Agents. 2020 Dec;56(6):106214.
   PubMed Web of Science ®Google Scholar
• Prodromos C, Rumschlag T. Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. New Microbes New Infect. 2020 Oct;38:100776.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Kelly RJ, Ruocco G, et al. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med. 2021 Aug;134(1):7.
   PubMed Web of Science ®Google Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020 Nov 19;383(21):2041–2052.
   PubMed Web of Science ®Google Scholar
• Group RC, Horby P, Mafham M, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Oct;8.
   Web of Science ®Google Scholar
• Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: a Randomized Clinical Trial. JAMA. 2020 Nov;9.
   Google Scholar
• Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020 Aug;97:396–403.
   PubMed Web of Science ®Google Scholar
• Yu B, Li C, Chen P, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020 Oct;63(10):1515–1521.
   PubMed Web of Science ®Google Scholar
• Sardu C, Marfella R, Maggi P, et al. Implications of AB0 blood group in hypertensive patients with covid-19. BMC Cardiovasc Disord. 2020 Aug 14;20(1):373.
   PubMed Web of Science ®Google Scholar
• Million M, Roussel Y, Gautret P, et al. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis. Int J Antimicrob Agents. 2021 Jan;57(1):106240.
   PubMed Web of Science ®Google Scholar
• Annie FH, Sirbu C, Frazier KR, et al. Hydroxychloroquine in Hospitalized Patients with COVID-19: real-World Experience Assessing Mortality. Pharmacotherapy. 2020 Oct;40(11):12.
   Web of Science ®Google Scholar
• Burkard C, Verheije MH, Wicht O, et al. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog. 2014 Nov;10(11):e1004502. .
   PubMed Web of Science ®Google Scholar
• Zhaowei Chen PH, Zhang Z, Jiang S, et al. ProfileZhan Zhang. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020.
   Google Scholar
• Plaze M, Attali D, Petit A-C, et al. Repositionnement de la chlorpromazine dans le traitement du COVID-19 : étude reCoVery. L’Encéphale. 2020 Jun;46(3):S35–S39.
   PubMed Web of Science ®Google Scholar
• Yesilkaya UH, Balcioglu YH, Sahin S. Reissuing the sigma receptors for SARS-CoV-2. J Clin Neurosci. 2020 Oct;80:72–73.
   PubMed Web of Science ®Google Scholar
• Brewer J, Gomez Marti JL, Brufsky A. Potential interventions for SARS-CoV-2 infections: zinc showing promise. J Med Virol. 2021 Sep;93(3):17.
   Web of Science ®Google Scholar
• Carlucci PM, Ahuja T, Petrilli C, et al. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. J Med Microbiol. 2020 Sep;69(10):15.
   Web of Science ®Google Scholar
• Martin SRD, Vladimir Z. Outpatients – early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: a Retrospective Case Series Study. Preprints 2020.
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — final Report. N Engl J Med. 2020 Oct 8;383(19):1813–1826.
   Web of Science ®Google Scholar
• Jockusch S, Tao C, Li X, et al. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. Sci Rep. 2020 Oct 6;10(1):16577.
   PubMed Web of Science ®Google Scholar
• Bryony Simmons HW, Mobarak S, Eslami G, et al. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19:an individual patient data meta-analysis. Journal of Antimicrobial Chemotherapy. 2020.
   Google Scholar
• Eslami G, Mousaviasl S, Radmanesh E, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother. 2020 Nov 1;75(11):3366–3372.
   PubMed Web of Science ®Google Scholar
• Juarez M, Schcolnik-Cabrera A, Duenas-Gonzalez A. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res. 2018;8(2):317–331.
   PubMed Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787.
   PubMed Web of Science ®Google Scholar
• Rajter JC, Sherman MS, Fatteh N, et al. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: the Ivermectin in COVID Nineteen Study. Chest. 2021 Oct;159(1):13.
   Web of Science ®Google Scholar
• Mahmud R. Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection.2020 [cited; Available from: https://clinicaltrials.gov/ct2/show/NCT04523831
   Google Scholar
• Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? Mol Med. 2020 May 7;26(1):42.
   PubMed Web of Science ®Google Scholar
• Chen L, Long X, Xu Q, et al. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cell Mol Immunol. 2020 Sep;17(9):992–994.
   PubMed Web of Science ®Google Scholar
• Yang M, Cao L, Xie M, et al. Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. Biochem Pharmacol. 2013 Aug 1;86(3):410–418.
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ, Barroso J, McCarty M. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart. 2020 Sep;7(2):2.
   Web of Science ®Google Scholar
• Schaller M, Gonser L, Belge K, et al. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1907–1911.
   PubMed Web of Science ®Google Scholar
• Draganov D, Gopalakrishna-Pillai S, Chen Y-R, et al. Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death. Sci Rep. 2015 Nov 10;5(1):16222.
   PubMed Web of Science ®Google Scholar
• Van Den Berg DF, Te Velde AA. Severe COVID-19: NLRP3 Inflammasome Dysregulated. Front Immunol. 2020;11:1580.
   PubMed Web of Science ®Google Scholar
• Van De Veerdonk FL, Netea MG. Blocking IL-1 to prevent respiratory failure in COVID-19. Crit Care. 2020 Jul 18;24(1):445.
   PubMed Web of Science ®Google Scholar
• Akula MK, Shi M, Jiang Z, et al. Control of the innate immune response by the mevalonate pathway. Nat Immunol. 2016 Aug;17(8):922–929.
   PubMed Web of Science ®Google Scholar
• Park YH, Wood G, Kastner DL, et al. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016 Aug;17(8):914–921.
   PubMed Web of Science ®Google Scholar
• Daniloski Z, Jordan TX, Wessels -H-H, et al. Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. Cell. 2021 Oct;184(1):24.
   Web of Science ®Google Scholar
• Perucha E, Melchiotti R, Bibby JA, et al. The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells. Nat Commun. 2019 Jan 30;10(1):498.
   PubMed Web of Science ®Google Scholar
• Akinci E, Cha M, Lin L, et al. Elucidation of remdesivir cytotoxicity pathways through genome-wide CRISPR-Cas9 screening and transcriptomics. bioRxiv. 2020 Aug;28. DOI:10.1101/2020.08.27.270819
   Google Scholar
• Renteria AE, Mfuna Endam L, Adam D, et al. Azithromycin Downregulates Gene Expression of IL-1β and Pathways Involving TMPRSS2 and TMPRSS11D Required by SARS-CoV-2. Am J Respir Cell Mol Biol. 2020 Aug;63(5):28.
   Web of Science ®Google Scholar
• Gomez Marti JL, Wells A, Brufsky AM. Dysregulation of the mevalonate pathway during SARS-CoV-2 infection: an in silico study. J Med Virol. 2020 Dec;17.
   PubMed Web of Science ®Google Scholar
• Nosaka N, Martinon D, Moreira D, et al. Autophagy Protects Against Developing Increased Lung Permeability and Hypoxemia by Down Regulating Inflammasome Activity and IL-1β in LPS Plus Mechanical Ventilation-Induced Acute Lung Injury. Front Immunol. 2020;11:207.
   PubMed Web of Science ®Google Scholar
• Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020 Jul;2(7):e393–e400.
   PubMedGoogle Scholar
• Nils Rother CY, Rik GH, Lindeboom SB, et al. Raphaël Duivenvoorden. Hydroxychloroquine inhibits trained immunity – implications for COVID-19. medRxiv 2020.
   Google Scholar
• Zhang X-J, Qin -J-J, Cheng X, et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020 Aug 4;32(2):176–87 e4.
   PubMed Web of Science ®Google Scholar
• Cote-Daigneault J, Mehandru S, Ungaro R, et al. Potential Immunomodulatory Effects of Statins in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Mar;22(3):724–732.
   PubMed Web of Science ®Google Scholar
• Brufsky A, Marti JLG, Nasrazadani A, et al. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. J Transl Med. 2020 Jun 29;18(1):261.
   PubMed Web of Science ®Google Scholar